AUDUBON, PA, July 1, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, announced the introduction of RISE®-L, a lateral lumbar interbody fusion (LLIF) device and the latest addition to the company’s leading portfolio of expandable spacers.

The LLIF procedure, approaching the spine from the side of the patient, allows for a larger implant footprint, and is less disruptive to lower back muscles as compared other approaches, which may result in less blood loss and faster recovery.

RISE®-L is a vertically expanding LLIF device designed to minimize impaction, maximize indirect decompression, and provide a large graft space optimal for fusion potential. The all-titanium implant is designed for up to 7mm of continuous in situ expansion and to provide restorative disc height with proper anatomical fit. Available in multiple sizes, in parallel or lordotic profiles, RISE®-L provides options for surgeons to address proper sagittal balance. A large single graft chamber can be filled with autogenous bone graft material after insertion and expansion to ensure even contact with both vertebral endplates.

“Over the last four years we have continued to build upon our unmatched family of expandable spacers, and I am proud of our product development team with the launch of RISE®-L. This new lateral cage eliminates the need to forcefully impact the cage into the disc space. Our expansion technology allows the RISE®-L cage to be placed in compact form, and expanded for optimal fit, and also includes a large port for easy graft delivery once expanded,” commented Andrew Iott, Senior Vice President of Product Development.

“Having used RISE®-L, I am encouraged by the results in my patients. This novel expandable cage addresses many issues with lumbar fusion devices on the market today. With all the benefits of the lateral approach as well as gentle cage insertion, in situ expandability, and robust lordotic options, RISE®-L offers a customized fit and less endplate disturbance. The implant has a graft chamber that is comparable to non-expandable cages as well as a large backfilling port for inserting additional graft material after expansion. RISE®-L is the most elegant solution for lateral interbody fusion on the market,” commented Kevin S. Cahill, MD, PhD, MPH, Spinal Neurosurgeon at Carolina Neurosurgery & Spine Associates.

Globus Medical has steadily innovated its lateral platform starting with the PATRIOT® TransContinental™ LLIF cage over six years ago by bringing to market several advanced treatment options including the CALIBER®-L expandable cage, InterContinental® plate-spacer, and PLYMOUTH® lateral plate. Each product can be used in conjunction with Globus Medical’s MARS™ and MARS™ 3V retractors.

Indications

The RISE® Spacer is a lumbar interbody fusion device intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). The RISE® Spacer is to be filled with autogenous bone graft material. This device is intended to be used with supplemental fixation.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Ed Joyce
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

AUDUBON, PA, July 9, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, will announce its financial results for the second quarter ended June 30, 2015 after the market close on Thursday, July 30, 2015. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors.

Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 5:30 p.m. Eastern Time. Globus invites all interested parties to join the call by dialing:

1-855-533-7141          United States Participants

1-720-545-0060          International Participants

There is no passcode for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at www.globusmedical.com/investors.

The call will be archived until Thursday, August 13, 2015. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 8132-2678.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Contact:

Ed Joyce
Director, Investor Relations
Phone: (610) 930-1800
Email:   investors@globusmedical.com
www.globusmedical.com

RISE^®-L is an expandable lateral lumbar fusion device that offers up to 7mm of expansion coupled with a large graft chamber and the ability to introduce autogenous bone graft in situ.

• Minimize Impaction
  RISE^®-L is inserted at a reduced height to minimize impaction and preserve endplate integrity.
• Maximize Indirect Decompression
  RISE^®-L offers controlled continuous expansion to aid in restoring disc height and maximize indirect decompression.
• Optimize Fusion
  RISE^®-L’s large continuous graft chamber, in combination with the ability to introduce additional bone graft in situ, is designed to allow bone graft to contact the vertebral endplates and optimize fusion potential.

 
The titanium implant provides continuous in situ expansion and is designed to restore disc height with proper anatomical fit. Available in multiple sizes, in parallel or lordotic profiles, RISE^®-L provides options for surgeons to address proper sagittal balance. A large single graft chamber can be filled with autogenous bone graft material after insertion and expansion to ensure even contact with both vertebral endplates.

Product Animation

KINEX^® PLUS Bioactive’s components are designed to recruit and signal osteoblasts, promote early vascular development and bind proteins necessary for bone regeneration. KINEX^® PLUS utilizes The Power of Bioactive Glass™ to help promote bone formation and healing in the posterolateral spine, pelvis, and extremities.

• Cell Recruitment and Signaling
  The regeneration of damaged bone tissue involves the migration and proliferation of osteoblasts to the site. Bioglass® recruits these cells and stimulates the production of growth factors that amplify the cellular activity responsible for bone formation. _{(1, 2, 3)}
• Angiogenic Potential
  Hyaluronic acid has been shown to help promote early vascularization and attracts osteogenic precursor cells, which may lead to earlier bone formation. _{(4, 5)}
• Protein and Cell Binding
  Collagen provides a resorbable osteoconductive scaffold that binds proteins and cells. _{(6, 7)}

KINEX^® PLUS Bioactive provides exceptional handling characteristics and is available as Putty and Gel.

• KINEX^® PLUS Putty: Moldable putty that is cohesive and easily packs into in the posterolateral spine or bone voids.
• KINEX^® PLUS Gel: Extrudable formula packaged in a luer lock syringe for controlled delivery.

1 Xynos ID, Edgar AJ, Buttery LDK, Hench LL, Polak JM. Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem. Biophys. Res. Commun. 2000; 276: 461–465.
2 Xynos ID, Hukkanen MV, Batten JJ, Buttery LD, Hench LL, Polak JM, Bioglass 45S5 Stimulates Osteoblast Turnover and Enhances Bone Formation In Vitro: Implications and Applications for Bone Tissue Engineering. Calcif. Tissue Int. 2000; 67: 321–329.
3 Ducheyne P, Qiu Q: Bioactive ceramics: the effect of surface reactivity on bone formation and bone cell function. Biomaterials 1999; 20: 2287–2303.
4 Sasaki T, Watanabe C. Stimulation of osteoinduction in bone wound healing by high-molecular weight hyaluronic acid. Bone 1995; 16: 9–15.
5 West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985; 14:1324–1326.
6 Morin R, Kaplan D, Perez-Ramirez B. Bone morphogenetic protein-2 binds as multilayers to a collagen delivery matrix: an equilibrium thermodynamic analysis. Biomacromolecules 2006; 7(1): 131–8.
7 Geiger M, Li, RH, Friess W. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev. 2003, 55: 1613–1629.

Globus Medical Reports Second Quarter 2015 Results
Reports Record Quarterly Sales and Increases Guidance

Download full report

AUDUBON, PA, July 30, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the second quarter ended June 30, 2015.

• Worldwide sales increased 17.6% to $133.6 million, or 19.1% on a constant currency basis
• Second quarter net income increased 16.5% to $24.1 million
• Fully diluted earnings per share (EPS) were $0.25
• Non-GAAP Adjusted EBITDA was 35.0% of sales
• Company increases 2015 guidance for sales to $524 million and EPS to $1.04

David Paul, Chairman and CEO said, “We are pleased to report second quarter sales of $133.6 million, a year-over-year increase of 17.6% as reported and 19.1% on a constant currency basis. Once again the Globus team achieved strong sales growth and market share gains while maintaining strong profitability, with quarterly net income of $24.1 million, or 16.5% higher than the same quarter last year. During the second quarter, we also launched 5 new products and made further progress on integrating our two most recent acquisitions. We remain confident in our long term growth prospects and our ability to sustain our industry leading profitability by the continued execution of our strategy of introducing innovative products, expanding our U.S. and international sales footprint, and controlling our expenses.”

Second quarter sales in the U.S. grew by 19.5% over the second quarter of 2014. International sales increased by 1.2% over the second quarter of 2014 on an as reported basis and 15.4% on a constant currency basis.

Second quarter net income was $24.1 million, an increase of 16.5% over $20.6 million in the second quarter 2014. Fully diluted EPS for the second quarter was $0.25, as compared to $0.22 for the second quarter 2014.

Cash, cash equivalents and marketable securities ended the quarter at $281.2 million. The company remains debt free.

2015 Annual Guidance
The company today increased guidance on sales by $10 million to $524 million and earnings per share by $0.02 to $1.04.

Conference Call Information

Globus Medical will hold a teleconference to discuss its 2015 second quarter results with the investment community at 5:30 p.m. Eastern Time today. Globus invites all interested parties to join the call by dialing:

1-855-533-7141 United States Participants
1-720-545-0060 International Participants
There is no pass code for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at investors.globusmedical.com.

If you are unable to participate during the live teleconference, the call will be archived until Thursday, August 13, 2015. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 8132-2678.

About Globus Medical, Inc.

Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Non-GAAP Financial Measures

To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, changes in the fair value of contingent consideration in connection with business acquisitions and other acquisition related costs, and provisions for litigation, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. In addition, for the periods ended June 30, 2015 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted earnings per share, which represent net income and diluted earnings per share, respectively, before provisions for litigation, net of the tax effects of such provisions. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operative performance from period to period as they remove the effects of litigation, which we believe are not reflective of underlying business trends. We also define the non-GAAP measure of Free Cash Flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, we define the non-GAAP measure of sales on a constant currency basis as the current and prior period sales translated at the same predetermined exchange rate. We believe that this sales on a constant currency basis provides insight to the comparative increase or decrease in period sales, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, Free Cash Flow and sales on a constant currency basis are not calculated in conformity with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, Free Cash Flow, and sales on a constant currency basis may differ from that of other companies and therefore may not be comparable.

Safe Harbor Statements

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Download full report
 

Contact:
Brian Kearns
Vice President of Business Development
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

The MARS™ ACDF Retractor has a small, sleek, stainless steel body with side-loading radiolucent titanium blades. The system is available with an assortment of blades including narrow blades for minimum soft tissue disruption and flared blades for maximum access through a small incision.

• Stable Platform
  Table arm attachment to secure the frame and help prevent shifting

• Secure Retraction
  Rigid connection between the blade and blade handle prevents rotation for an easy transition to the retractor frame

• MIS Access
  Comprehensive blade offering including narrow blades for minimal soft tissue disruption and flared blades for maximum access through a minimal incision

The ALLOCATE™ Cannula Kit provides the instruments necessary for consistent and controlled delivery of KINEX® Bioactive Gel, KINEX® PLUS Bioactive Gel, and CONDUCT® Matrix Putty.

• Controlled Delivery
  Transparent syringe and cannula provide visual feedback for consistent and controlled delivery.
• Precise Application
  Flexible cannula allows for precise placement and access to surgical sites that are not easily accessible.
• Visualization of Placement
  Radiopaque marker band on the cannula tip allows for visualization in minimally invasive procedures.

Audubon, PA, August 31, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced that James R. Tobin has been appointed to the company’s Board of Directors.

Mr. Tobin served as President and Chief Executive Officer of Boston Scientific from March 1999 to July 2009 during which time the company’s revenues grew from more than $2 billion to over $8 billion. During his tenure, Boston Scientific achieved a number of significant milestones, including the successful commercial launch of numerous products, significant acquisitions and strategic alliances (including the transformative acquisition of Guidant Corporation), and the growth of Boston Scientific’s international business to more than 40% of the company’s annual revenues. Before joining Boston Scientific, Mr. Tobin served as President and CEO of Biogen Inc., where he was instrumental in making it one of the world’s most successful biotechnology companies. Prior to joining Biogen, Mr. Tobin was an executive with Baxter International. He became President and Chief Operating Officer of Baxter in 1992 and was responsible for all operations of the $9 billion company. Mr. Tobin holds an M.B.A. from Harvard Business School and an A.B. from Harvard College.

“We are excited to welcome Jim to our Board of Directors,” said David Paul, Globus Medical’s Chairman and Chief Executive Officer. “Jim has developed extensive expertise in the medical technology industry, both domestically and internationally, over his career. We will greatly benefit from his management and operational experience as we continue to implement our strategic plan of introducing innovative products, expanding our domestic and international sales forces, and making focused acquisitions.”

“I am honored to join Globus Medical’s Board of Directors,” said Mr. Tobin. “Globus is a proven innovator in the musculoskeletal industry and has built an incredibly strong organization with industry leading profitability by focusing on the needs of its surgeon customers and their patients. I look forward to working with the other directors and the management team and contributing to the future direction and growth of this dynamic company.”

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Contact:
Dan Scavilla
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

• Dave Demski named Group President, Emerging Technologies
• Anthony Williams named President of Globus Medical
• Brett Murphy named Group President, Commercial Operations

Audubon, PA, September 8, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced a new leadership structure to enhance organizational alignment and continue the Company’s industry leading revenue growth and operating performance into the future.

Globus Medical’s President and Chief Operating Officer, Dave Demski, will transition from that role and assume the position of Group President, Emerging Technologies. In Mr. Demski’s new role he will focus on long-term strategic initiatives including robotics, trauma and other related opportunities for long term growth. Mr. Demski will also continue to be a primary liaison between the company and its investor, surgeon and hospital constituents. Mr. Demski will report to David Paul, Chairman and Chief Executive Officer, and work with the Board of Directors and our executive team to formulate the long-term strategic direction of the company.

“Emerging Technologies will be a major part of Globus’ strategy for long term growth. My experience and primary interest is with building new businesses and helping them grow to realize their potential. I’m excited to be able to focus my efforts on helping Globus achieve its goals in this important area,” Mr. Demski said.

Anthony Williams, Globus’ current Senior Vice President of Business Development and General Counsel, will assume the role of President of Globus Medical. This promotion comes after 12 years associated with the company in various capacities. Mr. Williams has been responsible for the company’s business development efforts since 2013, during which time he was instrumental in completing several strategic acquisitions intended to help Globus achieve its goal of industry-leading profitable growth.

“Anthony has been involved with Globus since we started the company in 2003, initially as our outside counsel and then as our General Counsel and head of Business Development. He has continued to add value and has taken on roles of increasing responsibility since he joined Globus on a full time basis in 2011, and I am delighted to appoint him as our next President,” Mr. Paul said.

Globus also plans to implement organizational changes in its sales and marketing departments to best service its healthcare customers. Brett Murphy, who is currently Globus’ Executive Vice President of US Sales, has been promoted to Group President, Commercial Operations reporting to David Paul and will now be responsible for Globus’ worldwide sales organization. “Brett joined Globus 10 years ago and has continued to assume roles of greater responsibility in our sales organization over that time,” stated David Paul. “His experience and knowledge of our business make him well qualified to assume leadership of our global sales and marketing efforts.”

These management changes were made to better align the company’s global organization with a focus on creating long term strategic value and ensuring profitable growth. “These appointments should help bring our innovative products to a greater number of customers in the US and internationally,” stated David Paul. “I look forward to helping more patients benefit from our leading technologies in the musculoskeletal marketplace.”

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Dan Scavilla
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

October 2015

We look forward
to seeing you
soon at
NASS in Chicago
October 14-17th,
2015
Booth #1459

Maximize Lumbar Lordosis

In Booth Presentations:

Lateral Techniques to Maximize Lumbar Lordosis
Wednesday, October 14th | 10:00 – 10:30am | Dr. Joseph O’Brien
Featuring RISE®-L and Direct Look®

TLIF Techniques to Maximize Lumbar Lordosis
Thursday, October 15th | 9:10 – 9:40am | Dr. Brad Prybis
Featuring ALTERA® and CREO MCS™

Globus Medical products highlighted at NASS

RISE®-L RISE®-L is an expandable lateral lumbar fusion device that offers up to 7mm of expansion coupled with a large graft chamber and the ability to introduce autogenous bone graft in situ. Learn More	ALTERA™ ALTERA™ is an articulating expandable TLIF spacer designed to maximize the potential for restoring lordosis and maintaining sagittal balance while minimizing the challenges of insertion. Learn More

FORGE^® Oblique Allograft Spacer is a cortical spacer designed to provide a natural option for transforaminal lumbar fusion. This spacer is available in multiple sagittal profiles and heights to accommodate varying patient anatomy and optimize fit. The FORGE^® system is designed to be used with innovative instruments to streamline the procedure.

• Precisely Machined for Strength and Fit:
  Designed to support cervical loads while maximizing surface contact between the graft and vertebral endplates.
• Gradual Bone Incorporation:
  Cortical composition provides a load-bearing scaffold that can be slowly resorbed and simultaneously replaced by the patient’s own bone.
• Sterile-Packed in Freeze-Dried Form:
  Packaging provides compact storage and easy shipping.

AUDUBON, PA, October 12, 2015: Globus Medical, Inc.<\/a> (NYSE:GMED), a leading musculoskeletal implant manufacturer, will announce its financial results for the third quarter ended September 30, 2015 after the market close on Tuesday, November 3, 2015. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors.

Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 5:30 p.m. Eastern Time. Globus invites all interested parties to join the call by dialing:

1-855-533-7141   United States Participants
1-720-545-0060   International Participants

There is no passcode for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at www.globusmedical.com/investors.

The call will be archived until Tuesday, November 17, 2015. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 6022-4510.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Contact:
Dan Scavilla
Senior Vice President and Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

Globus Medical Reports Third Quarter 2015 Results
Reports Record Quarterly Sales and Increases Guidance

Download the full report here

AUDUBON, PA, November 3, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced its financial results for the third quarter ended September 30, 2015.

• Worldwide sales increased 16.3% to $137.0 million, or 17.6% on a constant currency basis
• Third quarter net income increased 14.8% to $26.5 million, or 18.0% on a constant currency basis
• Fully diluted earnings per share (EPS) were $0.28
• Non-GAAP Adjusted EBITDA was 36.9% of sales
• Company increases 2015 guidance for sales to $539 million and EPS to $1.07

 
David Paul, Chairman and CEO said, “We are pleased to report third quarter sales of $137 million, a year-over-year increase of 16.3% as reported and 17.6% on a constant currency basis. Once again the Globus team achieved strong sales growth and market share gains while maintaining industry leading profitability, with quarterly net income of $26.5 million, or 14.8% higher than the same quarter last year. During the third quarter, we also launched 3 new products and made further progress on integrating our two most recent acquisitions. We remain confident in our long term growth prospects and our ability to sustain our industry leading profitability by the continued execution of our strategy of introducing innovative products, expanding our U.S. and international sales footprint, and controlling our expenses.”

Third quarter sales in the U.S. grew by 17.9% over the third quarter of 2014. International sales increased by 1.2% over the third quarter of 2014 on an as reported basis and 14.6% on a constant currency basis.

Third quarter net income was $26.5 million, an increase of 14.8%, or 18.0% on a constant currency basis. Fully diluted EPS for the third quarter was $0.28, as compared to $0.24 for the third quarter 2014.

Cash, cash equivalents and marketable securities ended the quarter at $300.1 million. The company remains debt free.

2015 Annual Guidance
The company today increased guidance for full year 2015 sales by $15 million to $539 million and earnings per share by $0.03 to $1.07. The increased sales guidance takes into account our expectations for $5.5 million unfavorable impact of foreign currency exchange.

Conference Call Information
Globus Medical will hold a teleconference to discuss its 2015 third quarter results with the investment community at 5:30 p.m. Eastern Time today. Globus invites all interested parties to join the call by dialing:

1-855-533-7141 United States Participants
1-720-545-0060 International Participants
There is no pass code for the teleconference.

For interested parties who do not wish to ask questions, the teleconference will be webcast live and may be accessed through a link on the Globus Medical website at investors.globusmedical.com.

If you are unable to participate during the live teleconference, the call will be archived until Tuesday, November 17, 2015. The audio archive can be accessed by calling 1-855-859-2056 in the U.S. or 1-404-537-3406 from outside the U.S. The passcode for the audio replay is 8132-2678.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Non-GAAP Financial Measures
To supplement our financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”), management uses certain non-GAAP financial measures. For example, Adjusted EBITDA, which represents net income before interest income, net and other non-operating expenses, provision for income taxes, depreciation and amortization, stock-based compensation, changes in the fair value of contingent consideration in connection with business acquisitions and other acquisition related costs, and provisions for litigation, is useful as an additional measure of operating performance, and particularly as a measure of comparative operating performance from period to period, as it is reflective of changes in pricing decisions, cost controls and other factors that affect operating performance, and it removes the effect of our capital structure, asset base, income taxes and interest income and expense. Our management also uses Adjusted EBITDA for planning purposes, including the preparation of our annual operating budget and financial projections. In addition, for the periods ended September 30, 2015 and for other comparative periods, we are presenting non-GAAP net income and non-GAAP diluted earnings per share, which represent net income and diluted earnings per share, respectively, before provisions for litigation, net of the tax effects of such provisions. We believe these non-GAAP measures are also useful indicators of our operating performance, and particularly as additional measures of comparative operative performance from period to period as they remove the effects of litigation, which we believe are not reflective of underlying business trends. We also define the non-GAAP measure of Free Cash Flow as the net cash provided by operating activities, adjusted for the impact of restricted cash, less the cash impact of purchases of property and equipment. We believe that this financial measure provides meaningful information for evaluating our overall financial performance for comparative periods as it facilitates an assessment of funds available to satisfy current and future obligations and fund acquisitions. Furthermore, we define the non-GAAP measure of sales and net income on a constant currency basis as the current and prior period sales and net income translated at the same predetermined exchange rate. We believe that sales and net income on a constant currency basis provides insight to the comparative increase or decrease in period sales and net income, in dollar and percentage terms, excluding the effects of fluctuations in foreign currency exchange rates.

Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, Free Cash Flow and sales and net income on a constant currency basis are not calculated in conformity with U.S. GAAP. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for financial measures prepared in accordance with U.S. GAAP. These measures do not include certain expenses that may be necessary to evaluate our liquidity or operating results. Our definitions of Adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, Free Cash Flow, and sales and net income on a constant currency basis may differ from that of other companies and therefore may not be comparable.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Download the full report here

Contact:

Daniel Scavilla
Senior Vice President, Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

AUDUBON, PA, November 9, 2015: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, will hold its Analyst Day meeting this Thursday, November 12, 2015. Globus Management’s audio presentation will be webcast live from 9:00am ET to 10:30am ET and may be accessed through a link on the Globus Medical website at www.globusmedical.com/investors. The management slideshow presentation will also be made available on the Globus Medical Investor Relations website.

After the presentation, the audio archive and the slideshow presentation can be accessed through a link on the Globus Medical website at www.globusmedical.com/investors.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Dan Scavilla
Senior Vice President and Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

CREO MIS™ is a posterior percutaneous stabilization system featuring extended screw heads. This system provides the same strength and rigidity as CREO^®, allowing for manipulation and deformity correction.

• Minimized Muscle Disruption – Extended screw heads provide a minimized outer diameter to help reduce muscle disruption and screw sleeve interference.
• Powerful MIS Correction – Deformity adapters rigidly attach to the extended screw head to allow for screw manipulation and deformity correction.
• Integrated Rod Reduction – Ensures proper thread alignment while capturing, reducing, and locking the rod in one simplified step.

MARS™3VL is a low-profile linear retractor system designed to facilitate easier and more controlled access. Its simplified design and enhanced functionality allow surgeons to focus more on surgery and less on setup.

• Versatility: Designed for faster, easier, and more controlled access to the disc space, MARS™3VL allows for posterior blade retraction as well as anterior movement of the cephalad/caudal blades from one docking point.
• Variability: Tailored to accommodate various surgeon preferences, the MARS™3VL retractor frame accommodates either a 13mm inner diameter (ID) three-bladed construct or a 22mm ID two-bladed split tube construct.
• Visibility: Radiolucent blades securely attach to the stainless steel frame providing the perfect combination of strength and visibility under fluoroscopy.

AUDUBON, PA, January 6, 2016: Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal implant manufacturer, today announced preliminary unaudited sales results for the fourth quarter and full year ending December 31, 2015, in advance of its annual national sales meeting being held later this week. The company anticipates fourth quarter 2015 sales of approximately $142.6 million, growing 10.7% as-reported or 11.5% in constant currency vs. fourth quarter 2014. Full year 2015 estimated sales are expected to be approximately $544.7 million, growing 14.8% as-reported or 16.0% in constant currency vs. the prior year, exceeding the company’s previous guidance of $539 million.

David Paul, Chairman and CEO, stated, “In 2015 we continued our focus on growing the business through expanding the sales force and launching innovative products. Our fourth quarter and full year results demonstrate the effective execution of our strategy, achieving strong sales growth and market share gains. We also continued to invest significantly in our Emerging Technologies platforms throughout the year for sustained, long-term growth potential. Looking to 2016, we are confident in our ability to continue to grow our business faster than the overall spine market.”

The company established full year 2016 guidance of $583 million in sales and fully diluted earnings per share of $1.20. “2016 EPS guidance reflects an increase in net income in line with our expected sales growth, as well as a positive contribution from the recently-announced suspension of the Medical Device Tax. The full impact of the suspended Medical Device Tax is expected to be about $0.06 per share. We plan to redirect approximately 40% of this benefit into increased job creation initiatives in R&D and Manufacturing in 2016. Our 2016 guidance reflects approximately 7% growth in sales and 10% growth in EPS over our expected 2015 results”, said Dan Scavilla, CFO.

These preliminary results are unaudited and are based on management’s initial analysis of operations for the periods ended December 31, 2015, and are therefore subject to change. The company expects to announce its fourth quarter and full year 2015 financial and operating results in late February.

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal implant company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Daniel Scavilla
Senior Vice President, Chief Financial Officer
Phone: (610) 930-1800
Email: investors@globusmedical.com
www.globusmedical.com

ELLIPSE^® ADDITION^®-C is the market’s only comprehensive revision implant system permitting connection between cervical constructs, as well as cervical to thoracolumbar constructs, with minimal disruption to the original surgical site. These implants may help reduce incision size and the surgical time associated with revision surgeries.

The ELLIPSE^® System is a comprehensive, easy-to-use solution for the toughest of cases.

• Less Disruptive Revisions: Ability to connect onto the existing construct minimizes the dissection area, potentially decreasing disruption to surrounding tissue.
• Fewer Steps in the Operating Room: No need to replace existing hardware, simply connect using one of the vast connector options.
• More Intraoperative Versatility: Comprehensive range of connectors and clamps that connect to systems such as PROTEX^® CT, REVERE^® and BEACON^® with rods ranging in diameter from 3.2mm to 6.5mm.